Drug Profile
Infliximab biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 03 Jul 2015 Research is ongoing in USA
- 18 Jun 2015 Infliximab biosimilar - Harvest Moon Pharmaceuticals is available for licensing as of 18 Jun 2015. www.harvestmoonpharma.com